InSitu Biologics Revenue and Competitors
Estimated Revenue & Valuation
- InSitu Biologics's estimated annual revenue is currently $3M per year.
- InSitu Biologics's estimated revenue per employee is $201,000
Employee Data
- InSitu Biologics has 15 Employees.
- InSitu Biologics grew their employee count by -6% last year.
InSitu Biologics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Clinical Operations and Regulatory Affairs | Reveal Email/Phone |
2 | Director Administration | Reveal Email/Phone |
3 | Chief Science Officer, Cofounder | Reveal Email/Phone |
4 | Chief Operating Officer | Reveal Email/Phone |
5 | President and CEO | Reveal Email/Phone |
InSitu Biologics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.9M | 69 | -13% | N/A | N/A |
#2 | $110.3M | 549 | -3% | N/A | N/A |
#3 | $14.1M | 70 | 1% | N/A | N/A |
#4 | $1051.4M | 5231 | -5% | N/A | N/A |
#5 | $55.9M | 278 | 22% | N/A | N/A |
#6 | $50.3M | 250 | N/A | N/A | N/A |
#7 | $2.2M | 22 | 214% | N/A | N/A |
#8 | $1.4M | 7 | -87% | N/A | N/A |
#9 | $68.1M | 339 | 17% | N/A | N/A |
#10 | $19.5M | 97 | 0% | N/A | N/A |
What Is InSitu Biologics?
InSitu Biologics, LLC is an emerging biotech company focusing on development of new and proprietary treatments using its Matrixâ„¢ BioHydrogel. Their lead product, AnestaGelâ„¢, is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management. AnestaGelâ„¢ uses a novel approach to delivering sustained-released analgesics into the target tissue via the Matrixâ„¢ BioHydrogel platform, which is a tunable, biocompatible, and pH neutral platform. This allows AnestaGelâ„¢ to provide target site-specific, non-migratory placement, a flexible and high dose drug-load reservoir capacity, and a tunable and predictable pharmacological effect.
keywords:N/A
N/A
Total Funding
15
Number of Employees
$3M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
InSitu Biologics News
InSitu Biologics: InSitu Biologics is an emerging biotech company focused on the development of a multi-phase prolonged-release drug delivery...
ImmunityBio Provides Updated Status of Biologics License Application (BLA) for ... Non-Muscle Invasive Bladder Cancer Carcinoma in Situ.
Merck Provides Update on FDA Review of Supplemental Biologics License ... Fee Act date of the supplemental biologics license application for...
Other Companies in Woodbury
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.4M | 16 | N/A | N/A |
#2 | $2.8M | 17 | 13% | N/A |
#3 | $3.5M | 18 | 6% | N/A |
#4 | $2M | 20 | 5% | N/A |
#5 | $2.1M | 21 | 0% | N/A |